Positive topline results were announced from a phase 3 study of obinutuzumab in patients with lupus nephritis.

Debaters Andres Chang, MD, PhD, and Jean Louise Koff, MD, MS, led the verbal battle at the Debates and Didactics in Hematology and Oncology Conference held from July 25 to 28, 2024, in Sea Island, ...

The trial met its primary endpoint showing a significant improvement in complete renal response with obinutuzumab with standard therapy vs standard therapy alone after 76 weeks. Positive topline ...

Swiss pharma giant Roche has announced positive top-line results from the Phase III REGENCY study of Gazyva/Gazyvaro ...

Roche has announced positive results from its phase III REGENCY study, showing that its drug Gazyva®/Gazyvaro® (obinutuzumab) ...

To provide more robust evidence for clinicians, investigators analyzed the efficacy and safety of biologics in patients with lupus nephritis using meta-regression analyses that adjusted for trials’ ...

Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus ...

Genentech announced positive results from the Phase III study (REGENCY) of Gazyva (Obinutuzumab) for people with active lupus nephritis (LN).

Roche announces positive results from phase III study of Gazyva/Gazyvaro in people with lupus nephritis: Basel Friday, September 27, 2024, 12:00 Hrs [IST] Roche announced positive ...

RHHBY announces meeting primary and key secondary goals in the late-stage study of its lymphoma drug, Gazyva/Gazyvaro, for ...